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This study evaluates the usefulness of serial provocative
electropharmacologic testing for predicting the efficacy
of prophylactic antiarrhythmic treatment regimens in
patients resuscitated from sudden cardiac arrest in the
absence of acute myocardial infarction. Testing was car-
ried out in 34 consecutive patients (28 men and 6 women)
who required cardiopulmonary resuscitation and direct
current countershock for treatment of primary ventric-
ular fibrillation (28 patients), ventricular tachycardia (5
patients) or excessively rapid heart rate during atrial
fibrillation with preexcitation (1 patient).
In 8 (24%) of the 34 patients, drug testing either was
not feasible because of absence of inducible arrhythmia
or was incomplete because of patient withdrawal from
study; and 3 of these 8 patients had recurrent sudden
Patients resuscitated after an episode of sudden cardiac arrest
are at particularly high risk for recurrence of life-threatening
arrhythmias, especially within the first year after the initial
episode (1-6). The estimated annual recurrence rate for
patients whose primary event occurred in the absence of
acute myocardial infarction approaches 25 to 40%. Con-
sequently, the development of techniques for assessment of
the effectiveness of prophylactic antiarrhythmic therapy in
these patients has been of increasing interest.
Recently, Ruskin et a1. (7,8) demonstrated that invasive
cardiac electrical stimulation techniques, similar to those
commonly utilized in many centers to assess therapy for
other cardiac arrhythmias, could be adapted safely for eval-
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cardiac arrest within 10 to 19 months. In an additional
five patients, treatment regimens failed to prevent ini-
tiation of sustained ventricular tachyarrhythmias in the
catheterization laboratory, and two of these fivepatients
had cardiac arrest recurrences within 2 weeks to 25
months of follow-up. In the remaining 21 (62%) of the
34 patients, including 3 patients with preexcitation syn-
drome, a drug regimen or surgical treatment, or both,
was found that prevented inducible life-threatening
tachyarrhythmias in the laboratory. Subsequently, only
1 (5%) of these 21 patients died suddenly within a 7 to
38 month (mean ± standard deviation, 18 ± 8.3) follow-
up period. Thus, provocative electropharmacologic test-
ing appears to be useful in predicting response to therapy
in survivors of sudden cardiac arrest.
uation of antiarrhythmic treatment in patients resuscitated
from sudden cardiac arrest. Furthermore, although based on
a small number of patients, treatment selection resulting
from findings during serial in-hospital electropharmacologic
testing yielded a reduction of the expected annual recurrence
rate of cardiac arrest to approximately 7%, thereby war-
ranting further assessment of this technique.
The object of this study was to evaluate provocative elec-
tropharmacologic testing as a tool for assessing the effec-
tiveness of prophylactic antiarrhythmic therapy in a series
of consecutive patients resuscitated after sudden cardiac ar-
rest. Our findings in 34 patients with a mean follow-up of
approximately 1 year suggest that treatments that prevent
reinitiation of previously provocable sustained arrhythmias
during electrical stimulation studies are associated with a
decreased recurrence rate of cardiac arrest in these high risk
patients.
Methods
Study Patients
Between September 1978 and January 1982, clinical
electrophysiologic studies (1 to 4 procedures/patient) were
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carried out in 34 consecutive patients referred for evaluation
of sudden out of hospital cardiac arrest. Cardiac arrest was
determined to have been present if the patient was unre-
sponsive when found and required cardiopulmonary resus-
citation and direct current cardioversion before initial hos-
pitalization . In all cases , ventricular fibrillation (28 patient s)
or ventricular tachycardia (5 patients) was diagnosed by
paramedical or emergency room personnel , or both , and in
19 cases, electrocardiographic record ings were obtained at
the time of resuscitation . Patients whose cardiac arrest either
was associated with acute myocardial infarction or occurred
as the result of an underlying debilitating condition were
not included in the study.
For purposes of this study, acute myocardial infarction
was said to have occurred if electrocardiographic evidence
of evolving transmural infarction was present, or if non-
specific electrocardiographic findings were associated with
a typical sequence of card iac enzyme elevation. It is pos-
sible, therefore , that some patients whose electrocardio-
graphic and enzyme changes were solely due to resuscitation
may have been excluded from the study . All patient s in-
cluded in the study group underwent electrophysiolo gic
evaluation within 6 weeks of card iac arrest. Thirty-one pa-
tients underwent coronary arteriography with left ventric-
ulograms.
Table 1 summarizes clinical and electrophysiologic find -
ings in the 34 pat ients (28 men, 6 women; age range 15 to
68 years) studied. Coronary artery disease as evidenced by
a history of previous (more than 4 months) myocardial in-
farction with compatible electrocardiographic abnormalities
or abnormal coronary arteriogram s, or both, was present in
20 (59%) of the 34 patients. Five patients had cardio -
myopathy (hypertrophic in one patient, postpartum in one
patient, idiopathic in three patients), four patients had a pri-
mary arrhythmia with no identifiable underlying heart dis-
ease , three patients had Wolff-Parkin son-White syndrome
and two patients had valvular heart disease. The arrhythmia
diagnosed at time of init ial resuscitation was ventricular
fibrillation in 28 (82%) of the 34 patients and ventricular
tachycardia in 5 patients. In one patient with Wolff-Parkin-
son-White syndrome (Patient 27) , atrial fibrillation resulted
in a ventr icular respon se exceeding 300 beats/min and was
associated with hemodynam ic collapse requi ring cardio-
version.
Electrophysiologic study. Before initial clinical elec-
troph ysiologic study, the procedure was care fully discussed
with each patient and written informed consent was ob-
tained . Patient s were advised that they could elect to decline
further testing at any time and, as a result , studies were
incomplete in 4 of the 34 SUbjects .
Patients were studied in the fasting state . Before the initial
study, all cardioactive drug s were discontinued for at least
three drug half-lives; however, card iac glycosides were not
withdrawn in those patients taking them before their cardiac
arrest. Two to four standard 6 French electrode catheters
were inserted percutaneously by way of the femoral or an-
tecub ital veins, or both , and positioned at specific intracar-
diac sites (right ventricular apex, His bundle recording site,
right atrium and coronary sinus) as needed. Cardiac elec-
trical stimulation was carried out using a custom-des igned
optically isolated stimulator capable of delivering up to four
independently timed sequential constant current extrastimuli
either during sinus rhythm or after a pacing train. Impul se
durat ion was usually 2 ms with current strength twice di-
astolic pacing threshold. Pulse width s greater than 2 ms
were employed only in patients treated with bethanidine
sulfate after it had been determined that protection again st
arrhythmia induction had been obtained at the standard 2
ms impulse duration.
For purposes of this study, sustained ventricular tachy-
cardia was diagnosed if a single episode was of 30 or more
QRS complexes in duration , or if hemodynamic impairment
was severe enough (that is, loss of consciousness) to require
termination of the arrhythmi a by pacing techn iques or direct
current countershock. Nonsustained ventricular tachycardia
was diagnosed if the tachyarrhythmi a consisted of less than
30 but more than 6 QRS complexes , and terminated spon-
taneously before hemod ynamic impairment became severe.
Pacing protocol. Ventricular pacing trains and extra-
stimuli were inserted at the right ventricular apex . In most
patients , the pacing protocol consisted of sequential inser-
tion of one to four extrastimul i after an 8 to 10 beat pacing
train at two fixed basic pacing cycle lengths (either 600 ms
[ I00 beats/min] and 500 ms [120 beats/min] or 500 ms [120
beats/min] and 400 ms [150 beats/min]). The choice of
pacing cycle lengths was dictated by the patients' hemo-
dynamic response to pacing (that is , development of hy-
poten sion or chest pain resulted in use of slower basic pacing
rates). Each extrastimulus was progressively scanned (10 to
20 ms decrements) through diastole until it no longer cap-
tured , at which point it was fixed 20 to 50 ms beyond the
point of refractoriness; the next extrastimulus was then added
and diastole scanned . This process was repeated until all
four extrastimuli were applied . The process was terminated
if sustained or reproducible nonsustained (see previously)
ventricular tachyarrh ythmi a was provoked .
If no arrhythmia was induced by these methods, right
ventricular burst pacing was initiated. The latter procedure
consisted of the insertion of two trains of six to eight ven-
tricular pacing beats spaced in time so that one or two sinus
beats occurred between the two trains. The pac ing cycle
length of each train was kept constant. If no arrhythmia was
induced , the cycle length of the train was reduced by 10
ms and the two train pacing sequence was repeated. Tra ins
were inserted over a range of cycle length s (usually 400 to
240 ms, 150 to 260 beats /min ), or until 1:1 capture in the
ventricle was no longer possible . It should be noted (Table
I) that in this study rapid pacing trains never initiated ven-
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tricular tachyarrhythmias when insertion of four sequential
extrastimuli had previously failed to do so. Nonetheless,
because use of burst pacing is conventional in provocative
electropharmacologic testing, it was employed in this pro-
tocol as an added measure to assess drug efficacy.
Because of the development of testing techniques over
time, the pacing protocol was less comprehensive in the
first 4 patients (Patients I to 4), than in the remaining 30
patients. Furthermore, for patients with Wolff-Parkinson -
White syndrome (Patients 17, 23 and 27) additional ex-
tensive studies were carried out to evaluate the electro-
physiologic characteristics and location of accessory atrio-
ventricular pathways. In these patients, special emphasis
was placed on analysis of ventricular cycle lengths during
pacing-induced atrial fibrillation (8).
Treatment regimens. In patients with inducible ven-
tricular arrhythmias, serial studies were carried out in the
presence of one or more antiarrhythmic treatment regimens
with a view toward establishing a treatment program that
prevented induction of either sustained or nonsustained ar-
rhythmia, or at least converted previously sustained ar-
rhythmias to nonsustained status. In some patients, it was
not possible to achieve either of these goals with standard
noninvestigational antiarrhythmic drugs, and several inves-
tigational antiarrhythmic agents (bethanidine sulfate, to-
cainide, amiodarone and flecainide acetate) were evaluated
after written informed consent was obtained. In patients in
whom surgery was performed, electrical stimulation studies
were repeated before hospital discharge.
Follow-up. After discharge from the hospital, patients
were followed up by their referring physicians. Follow-up
information was updated every 2 to 3 months on the basis
of telephone contact with either the patient or the patient's
physician; a minimal follow-up interval of 8 months was
obtained in all cases.
Results
Inducible ventricular arrhythmias. Potentially life-
threatening arrhythmias were induced during initial electro-
physiologic study in 30 (88%) of the 34 patients, whereas
in 4 patients, either no arrhythmia or only single ventricular
premature beats were observed . The extrastimulus se-
quences required to induce ventricular tachyarrhythmias in
the absence of drugs are indicated in Table 1. In the five
patients whose cardiac arrest was associated with ventricular
tacchycardia, it was possible to induce sustained ventricular
tachycardia , it was possible to induce sustained ventricular
tachycardia during catheterization laboratory study in four
patients and nonsustained ventricular tachycardia in one pa-
tient. On the other hand, of the 28 patients presenting with
out of hospital ventricular fibrillation, the most frequent
arrhythmia induced (in 20 patients) was a rapid ventricular
tachycardia (heart rate 180 to 340 beats/min) usually asso-
ciated with hypotension and often necessitating direct cur-
rent countershock. The induced rapid ventricular tachy-
cardia initially exhibited a relatively regular rhythm as detected
on the intraventricular electrogram, but often manifested a
polymorphic appearance on the surface electrocardiogram
(Fig. 1). Consequently, differentiation of polymorphic from
monomorphic ventricular arrhythmias did not appear to be
of practical clinical significance in this patient subgroup.
Association with ventricular fibrillation. The associ-
ation of inducible rapid ventricular tachycardia with occur-
rence of ventricular fibrillation in these patients is illustrated
by findings in Patient 16 in whom ventricular fibrillation
was documented after sudden collapse at home. While in
the hospital awaiting electrophysiologic study, she had a
second spontaneous cardiac arrest, and a rapid ventricular
tachycardia was recorded at its initiation (Fig . IA). Sub-
sequently, electrical stimulation studies reproduced a similar
tachyarrhythmia in the laboratory (Fig. 18) .
WolfT-Parkinson-White syndrome. In the two patients
with Wolff-Parkinson-White syndrome and documented out
of hospital ventricular fibrillation (Patients 17 and 23), rapid
ventricular responses during atrial fibrillation (shortest RR
interval less than 220 ms in each patient) were documented
during electrophysiologic study (9). Ventricular fibrillation
did not recur in the laboratory. In fact, ventricular fibrillation
did not occur during catheter study in any of the patients
presumably because of prompt termination of hemodyn-
amically serious arrhythmias by pacing techniques or direct
current countershock. However, as noted previously, the
surface electrocardiogram during induced ventricular tachy-
cardia frequently exhibited a polymorphic appearance that
may be difficult to distinquish from ventricular fibrillation
in the absence of intracardiac recordings. No deaths or com-
plications were associated with these studies.
Selection and results of antiarrhythmic treatment.
Table 2 summarizes both the various antiarrhythmic drugs
tested in this study and the frequency with which these
agents were a part of the final treatment regimen. Several
factors played a role in selection of drugs for testing in
individual patients; for example, the patient's hemodynamic
status, allergies, previously documented drug intolerance
and availability of investigational agents influenced the pro-
tocol. In addition, anatomic factors demonstrated by angi-
ography altered treatment recommendations in certain pa-
tients. For example, the presence of a ventricular aneurysm
or discrete regional dyskinesia associated with inducible
ventricular tachyarrhythmias was considered to be a poten-
tially surgically treatable condition . As a result, in 11 pa-
tients cardiac surgery was advised and, when appropriate,
was carried out with the aid of intraoperative electrophys-
iologic mapping (coronary artery bypass grafting alone in
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Table 1. Clinical Features and Electrophysiologic Findings
Arrhythmia
Patient Pnncipal Induced Effective
and Age (yr) Cardiac Presenting During EP Extrasnrnulus Drug Therapy
Group &Sex Diagnosis Arrhythmia Study Sequence Surgery at Discharge Follow-Up (mo)
IE 15M PEHD VF None N/A None Prop 13 (sudden death)
2E 61M CAD VF Single VPBs N/A CABG Prop 10 (sudden death)
3E 42M CM VF Single VPBs N/A None Proc 38
40 18F PEHD VF VT(NS) 2 None Prop. Ph* VF at 19 mo;
(alive at 38 mol
5A 54M CAD VF VT 2 None Proc Ph 38
6A 56M CAD VF VT 3 None Beth. Q 38
7C 68F PEHD VF VT 2 ER, EEV None 5 (sudden death)
8A 66M CAD VF VT 2 ER,CABG Q 26t
9C 52M CAD VF VT 3 None Proc, Ph 25
100 52F VHD VF VT 2 None Proc' 37
IIA 29M PEHD VF VT 3 None Proc 27
12E 68M CAD VT None N/A None None 40
13A 56M CAD VF VT 2 ER.CABG Q 20
14A 49M CAD VF VT 3 ER.CABG None 20
15A 40M CAD VT VT 3 CABG None 22
16A 28F CM VF VT 3 None Q 7 (sudden death)
17B 48M WPW VF AF. PSVT N/A None Prop. Q 34
18A 45M CAD VF VT 2 None Beth 19
19C 57M CM VF VT 3 None Toc 2 wk (sudden
death)
20A 49M CAD VF VT 2 None Prop 23
21A 47M CAD VF VT I ER.CABG Proc 16
220 59M CAD VF VT 3 None Diso" 15
23B IBM WPW VF AF, PSVT N/A AP None None
ablation
24A 55F CM VF VT 3 None Beth 12
25A 55M CM VT VT (NS) 2 None Proc, Toc 20
26C 56F CAD VF VT 2 None Anno 11
27B 15M WPW AF with rapid AF,PSVT N/A AP None II
ventricular ablation
response
28A 65M CAD VF VT 2 ER,CABG None I I
29A 55M CAD VF VT I None Prop 12
300 54M CAD VT VT 3 None Proc' 12
31A 64M CAD VF VT 3 EEV Prop 12
32C 67M CAD VF VT 3 None Amio 12
33A 67M VHD VF VT 2 None Proc, Ph 29
34A 52M CAD VF VT 2 Previous Flee, Prop 28
CABG
• Complete evaluation declined following entry into study. t DIed of congestive heart failure
AF = atrial fibrillation; Amio = amiodarone; AP = accessory bypass pathway: Beth = bethamdine (bretyliurn analog): CABG = coronary artery
bypass grafting; CAD = coronary artery disease: CM = cardiomyopathy: Diso = drsopyrarmde: EEV = encircling endocardial ventriculotomy; ER =
endocardial resecuon, Flee = flecainide: N/A = not available; NS = nonsustained «30 complexes), PEHD = " primary electnca l heart disease" : Ph
= phenytoin; Proc = procamamide; Prop = propranolol; PSVT = paroxysmal supraventricular tachycardia: Q = quinidine; SO = standard devianon:
Toe = tocainide; VF = ventncular fibrillation; VHD = valvular heart disease: VPB = ventricular premature beat: VT = ventricular tachycardia
(sustained); WPW = Wolff-Parkinson-Whrte syndrome.
one patient and aneurysmectomy and endocardial resection
in five patients, endocardial resection or encircling endo-
cardial ventriculotomy, or both , in two patients , accessory
atriove ntricu lar bypass tract ablation in two patients). How-
ever , the efficacy of card iac surgery, as with drug therapy,
was assessed by electrical stimulation studies before hospital
discharge . Therefore , for purposes of this study , both drugs
and cardiac surgery were considered to be forms of antiar-
rhythmic prophylaxis and were used in conjunction with
each other when deemed appropri ate .
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Table 2. Drugs Utilized in Electropharmacologic Testing
* Several patients were discharged on more than one agent (see Table
I). t Investigational drug. :/: Propranolol was irutially utilized in patients
whose studies were madcquate (see Table I, Patients 1,2 and 4), and was
associated wah recurrence of cardiac arrest in three of seven patients.
§ Utilized only as a second agent in conjunction with other antiarrhythmic
therapy.
Figure 1. Electrocardiographic and intracardiac recordings in Pa-
tient 16. A, Electrocardiographic recording obtained by in-hospital
telemetry demonstrating spontaneous onset of a rapid ventricular
tachycardia (cycle length 180 to 280 ms, heart rate 214 to 333
beats/min) resembling torsade de pointes (14,15). The patient was
being monitored before electrophysiologic evaluation of an out of
hospital episode of documented ventricular fibrillation 2 weeks
earlier and was receiving no cardiac medications. Direct current
cardioversion (not shown) terminated the tachycardia promptly and
sinus rhythm was restored. B, Electrocardiographic recordings
(leads I, II and III) and intracardiac right ventricular (RV) elec-
trogram during electrophysiologic study in the absence of antiar-
rhythmic drugs. At left, a 10 beat sequence of right ventricular
pacing (cycle length 500 ms, heart rate 120 beats/min) was ter-
minated by three sequential extrastimuli coupling intervals (SI -
Sz = 210 ms, Sz - S3 = 210 ms, S3 - S4 = 350 ms). Before
capture of the third extrastimulus, a sustained rapid ventricular
tachycardia (cycle length 180 to 210 ms, heart rate 286 to 333
beats/min) was initiated. The induced tachyarrhythmia was similar
to the patient's spontaneous tachycardia, exhibiting features
suggestive of torsade de pointes. Direct current cardioversion was
required to restore sinus rhythm.
No single antiarrhythmic drug regimen proved to be most
effective. In particular, although Table 2 suggests that pro-
pranolol was a consistently useful agent, this is somewhat
misleading because in the early stages of the study pro-
pranolol was selected for treatment of patients in whom
electrophysiologic studies were inadequate to define ther-
apy. Indeed, three of six patients treated with propranolol
as the principal antiarrhythmic agent had recurrence of out
of hospital cardiac arrest, and two of these patients died.
In general, available standard antiarrhythmic agents were
effective alone or in combination in the majority of patients
studied (Table I).
Follow-up results correlated with initial electrophys-
iologic study and drug testing. Figure 2 summarizes the
results of in-hospital evaluation and subsequent follow-up
(range 2 weeks to 40 months) for all 34 patients. The patients
were classified into five groups (A to E). In 4 of the 34
patients (Patients 1,2,3 and 12) either no arrhythmia or only
ventricular premature beats were elicited during initial lab-
oratory study; consequently serial drug testing was not fea-
sible (Fig. 2, group E). Two of these four patients have had
recurrence of out of hospital cardiac arrest. Similarly, in 4
of the remaining 30 patients (Patients 4,10,22 and 30) serial
testing was terminated before completion of the protocol
(Fig. 2, group D), and subsequent therapy was empiric. One
of these four patients (Patient 4) subsequently had recurrence
of out of hospital cardiac arrest at 19 months but is alive at
38 months.
In five patients (Patients 7,9,19,26 and 32) (Fig. 2, group
C), an antiarrhythmic treatment regimen that prevented ini-
tiation of sustained tachyarrhythmias during serial electro-
pharmacologic testing was not found. Two (40%) of these
five patients had recurrence of out of hospital cardiac arrest
at 2 weeks and 5 months, respectively. In one of these
subjects (Patient 7), combined endocardial resection and
encircling endocardial ventriculotomy was carried out with
the aid of intraoperative mapping. However, postoperatively
a sustained ventricular tachyarrhythmia was still inducible
(requiring four closely coupled extrastimuli compared with
Drug
I. Procainamide
2 Quinidine
3. Bethanidinet (bretylium analog)
4. Propranolol]
5. Lidocame
6. Bretylium
7. Phenytoin (diphenylhydantoin)§
8 Disopyramide phosphate
9. Amiodaronet
10. Tocaindet
II. Verapamil
12. Flecamidet
No. of
Patients Tested
17
II
7
8
6
4
3
2
5
2
I
I
DIscharged
on Drug*
8
5
3
8
o
o
4
I
2
2
o
I
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preoperative initiation using two extrastimuli), and this pa-
tient died suddenly 5 months later. Patients 26 and 32 were
treated empirically with amiodarone and are alive at 11 and
12 months, respectively.
In 21 patients (Fig. 2, groups A and B), electrophysio-
logic pharmacologic testing appeared to define appropriate
treatment. Accessory bypass tract ablation was advised and
carried out in two of three patients in group B with Wolff-
Parkinson-White syndrome: the third patient declined sur-
gery and was treated with a combination of quinidine and
propranolol. All group B patients are alive. Drug and sur-
gical regimens for the 18 patients in group A are provided
in Table 1. In these 18 patients, efficacy of therapy was
determined by repeat extrastimulus testing and was defined
as successful completion of the entire stimulation protocol.
During follow-up, 1(6%) of the 18 group A patients (Patient
16) had recurrence of sudden cardiac arrest; 1 other patient
(Patient 8) died 26 months after the study as a result of
congestive heart failure.
Discussion
The results of this study provide three principal obser-
vations. First, patients resuscitated from sudden out of hos-
pital cardiac arrest usually exhibited susceptibility to initi-
ation of sustained, potentially lethal ventricular arrhythmias
during programmed electrical stimulation studies. Second,
the most common arrhythmia initiated during electrophys-
iologic study was a rapid ventricular tachycardia, and al-
though ventricular fibrillation did not occur during the study,
its ultimate occurrence would likely have been inevitable
given the marked hemodynamic compromise usually as-
sociated with the rapid ventricular tachyarrhythmia induced.
Third, efficacy of antiarrhythmic therapy was predicted by
response to cardiac electrical stimulation before hospital
discharge. During comparable follow-up periods (excluding
3 group B patients who had Wolff-Parkinson-White syn-
drome), only a single cardiac arrest has occurred among 18
patients in whom an effective medical or surgical treatment
regimen, or both, was predicted by laboratory evaluation,
compared with recurrence in 5 (38%) of I3 patients in whom
catheter studies either suggested lack of treatment efficacy
(Fig. 2, group C) or were inadequate (Fig. 2, groups D and
E).
Routine prophylactic antiarrhythmic treatment for
survivors of cardiac arrest. In the past several years, a
consensus has evolved in regard to the importance of pro-
phylactic antiarrhythmic treatment for patients resuscitated
after sudden cardiac arrest. Several approaches have been
advocated. It has been proposed that adequate prophylaxis
could be provided by careful maintenance of currently ac-
cepted standard therapeutic antiarrhythmic drug levels (5,10-
Figure 2. Diagram summarizing the results of electropharrnacol-
ogic (EP) studies and follow-up in 34 survivors of sudden cardiac
arrest (SeA). VF = ventricular fibrillation, VPB's = ventricular
premature beats; VT = ventricular tachycardia: WPW = Wolff-
Parkinson-White syndrome.
INITIAL
EP STUDY
34 SeA Patients
VTIVF initiated or ba-sis of
presenting arrhythmia determined
30/34(88%)
No inducible arrhythmia
or VPB's only
4/34(12%)
STATUS
ON SELECTED
THERAPY
FOLLOW-UP
PERIOD
SCA
RECURRENCE(t)
A
VT/VF (18/30)
No inducible
arrhythmia
WPW (3/30)
2/3-surgery
1/3-drugs
34 months
11 months
15 months
0/3(0")
VTlVF (5/30)
Inducible
arrhythmIa
present
I
2 weeks(t)
11 months
5 months(t)
25 months
12 months
I
I2/5(40") I
VTIVF (4/30)
Complete
EP studIes
declined
12 months
15 months
19 months(t
27 months
E
13 months(t)
10 months(t)
38 months
40 months
)2/4(50") I
TESTING INCOMPLETE OR NOT FEASIBLE
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12). In this regard, Myerburg et at. (II) reported findings
in 16 patients followed up on a plasma level-monitored
treatment regimen. During follow-up, eight patients (50%)
had recurrent cardiac arrest and all were found to have had
unstable plasma drug levels before recurrence, while in six
of the eight patients without cardiac arrest recurrence, stable
therapeutic drug levels had been documented. Recently,
empiric prophylactic amiodarone therapy for sudden cardiac
arrest survivors has also been suggested to diminish recur-
rence rates. Nademanee et al. (13) noted only four recur-
rences of cardiac arrest among 24 patients (16%) during a
follow-up period of 4 days to 23 months, whereas Peter et
al . (14) reported four deaths among 27 patients (15%) treated
empirically with amiodarone for 5 to 22 months. In addition,
Morady et at. (15) reported only two recurrences of tachy-
cardia during an 18 ± 14 month follow up period in 23
survivors of cardiac arrest treated with amiodarone after
conventional antiarrhythmic drugs had failed to prevent ven-
tricular tacharrhythmias during electropharmacologic testing.
Use of ventricular stimulation techniques to select op-
timal antiarrhythmic treatment. An alternative approach
for selection of antiarrhythmic therapy in resuscitated vic-
tims of sudden cardiac arrest has been proposed by Ruskin
et al. (7,8). With the use of programmed right ventricular
electrical stimulation techniques, prevention of ventricular
arrhythmia induction by antiarrhythmic treatment was pos-
sible in 19 (61%) of the 31 subjects. Subsequently, there
were no recurrences of cardiac arrest in the latter 19 patients
over a mean 15 month follow-up, compared with 3 recur-
rences among the remaining 12 patient s. Recently, these
same investigators have updated and essentially reconfirmed
their initial experience (8). It is important to note, however,
that their findings now make clear that despite optimal an-
tiarrhythmic therapy many patients will nonetheless die non-
arrhythmic deaths during the follow-up period, presumably
because of progression of underlying heart disease.
The relative ease of inducing potentiall y life-threatening
arrhythmias during electrical stimulation studies in 30 (88%)
of our 34 patients closely parallel s the results reported by
Ruskin et at. (7 .8), and is similar to the recent findings of
Morady et al. (15), who induced ventricular tachyarrhyth-
mias in 76% of patients. In addition , although ventricular
fibrillation was the most frequent arrhythmia documented
on initial presentation in both this study (28 of 34, 82%)
and those of Ruskin et at. (23 of 31,74%), a rapid he-
modynamically unstable ventricular tachycardia was the ar-
rhythmia most often initiated during electrophysiologic test-
ing in both series. The results in both our study and those
of Ruskin's group differ somewhat with the observations of
Josephson et at. (16), who reported induction of sustained
or nonsustained ventricular tachycardia in only 9 (30%) of
30 patients presenting with ventricular fibrillation, whereas
ventricular fibrillation did occur in the laboratory in 4 sub-
jects. An explanation for this discrepancy is not apparent.
Implications of study. Our findings further support those
of Ruskin et al. (7,8) in that establi shment of a treatment
regimen that appeared to suppress laboratory arrhythmia
induction in 21 (62%) of our 34 patients was associated
with only one subsequent cardiac arrest during the follow-
up period , compared with five recurrences among the re-
maining 13 patients. Indeed, the reduction in the rate of
recurrence of cardiac arrest documented in those cases in
which an antiarrhythmic regimen was predicted to be ef-
fective in the laboratory was similar to that noted by Ruskin
et at. (7,8) and appeared to be an improvement compared
with previously reported historical controls (1-4,6). Con-
sequently, our findings support the view that serial electro-
physiologic testing is useful to predict effectiveness of pro-
phylactic antiarrhythmic therapy in survivors of out of hos-
pital cardiac arrest. However, follow-up in our patients has
been relatively short, and an ongoing surveillance to doc-
ument long-term results is necessary to establish an appro-
priate role for provocative electropharmacologic testing in
these high risk patients. Furthermore, the optimal treatment
for patients in whom ventricular tachyarrhythmias cannot
be induced in the laboratory , or in whom antiarrhythmic
therapy fails to prevent arrhythmia induction in the electro-
physiologic laboratory, remains a critical unanswered
question .
We express appreciation to the Card iac Cathetenzanon Laboratory staff.
the many cardiology fellow s who assisted WIth these studies and to Wend y
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